• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非异型增生性 Barrett 食管中食管腺癌的发病率:一项荟萃分析。

The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis.

机构信息

Department of internal medicine, William Beaumont Hospital, Royal Oak, Michigan, USA.

出版信息

Gut. 2012 Jul;61(7):970-6. doi: 10.1136/gutjnl-2011-300730. Epub 2011 Oct 13.

DOI:10.1136/gutjnl-2011-300730
PMID:21997553
Abstract

INTRODUCTION

The risk of oesophageal adenocarcinoma (OAC) in non-dysplastic Barrett's oesophagus (BO) may have been overestimated. The objective was to estimate the incidence of OAC in patients with BO without dysplasia.

METHODS

The authors searched MEDLINE and EMBASE from 1966 to 2011 and performed a bibliographic review of previous publications, excluding abstracts, non-peer-reviewed publications and those not published in English, for prospective or retrospective studies of the incidence of OAC in patients with BO. They excluded patients with any degree of dysplasia at baseline and those without documented intestinal metaplasia. Studies were independently reviewed by two individuals. 57 of 3450 studies were included. The authors extracted information on number of patients with BO, length of follow-up, incident cases of OAC, mean age of patients, country of origin, whether prospective or retrospective, mean length of BO segments and mortality from causes other than OAC. Study quality was assessed by the Ottawa Newcastle criteria.

RESULTS

The 57 included studies comprised 11,434 patients and 58,547 patient-years of follow-up. The pooled annual incidence of OAC was 0.33% (95% CI 0.28% to 0.38%). Among 16 studies that provided appropriate information on mortality, there were 56 incident cases of OAC but 684 deaths from apparently unrelated causes. Among 16 studies that provided information on patients with short-segment BO, the annual incidence of OAC was only 0.19%.

CONCLUSIONS

The incidence of OAC in non-dysplastic BO is around 1 per 300 patients per year. The incidence of OAC in short-segment BO is under 1 per 500 patients per year.

摘要

简介

非异型增生 Barrett 食管(BO)患者发生食管腺癌(OAC)的风险可能被高估了。本研究旨在评估无异型增生的 BO 患者发生 OAC 的发病率。

方法

作者检索了 1966 年至 2011 年 MEDLINE 和 EMBASE 数据库,并对先前发表的文献进行了综述,排除了摘要、非同行评审出版物和非英文出版物。研究纳入了前瞻性或回顾性评估 BO 患者 OAC 发病率的研究。研究排除了基线时存在任何程度异型增生或无肠化生证据的患者。由两名作者独立对研究进行了评估。在 3450 篇文献中,有 57 篇被纳入。作者提取了 BO 患者人数、随访时间、OAC 发病例数、患者平均年龄、来源国家、前瞻性或回顾性研究、BO 段平均长度以及非 OAC 相关死亡例数等信息。使用渥太华-纽卡斯尔评价标准对研究质量进行了评估。

结果

纳入的 57 项研究共包含 11434 例患者和 58547 患者年的随访时间。OAC 的年发病率为 0.33%(95%CI 0.28%~0.38%)。在提供了 OAC 死亡率相关信息的 16 项研究中,共有 56 例 OAC 发病,但有 684 例死亡与 OAC 无关。在提供了短节段 BO 患者信息的 16 项研究中,OAC 的年发病率仅为 0.19%。

结论

非异型增生 BO 患者 OAC 的发病率约为每年每 300 例患者中发生 1 例。短节段 BO 患者 OAC 的发病率约为每年每 500 例患者中发生 1 例。

相似文献

1
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis.非异型增生性 Barrett 食管中食管腺癌的发病率:一项荟萃分析。
Gut. 2012 Jul;61(7):970-6. doi: 10.1136/gutjnl-2011-300730. Epub 2011 Oct 13.
2
Meta analysis: Cancer risk in Barrett's oesophagus.荟萃分析:巴雷特食管的癌症风险
Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77. doi: 10.1111/j.1365-2036.2007.03528.x. Epub 2007 Sep 26.
3
Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.短节段巴雷特食管的发育异常:一项为期3年的前瞻性随访研究
Am J Gastroenterol. 1997 Nov;92(11):2012-6.
4
Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus.巴雷特食管患者发生食管腺癌的风险。
Eur J Cancer. 2017 Apr;75:41-46. doi: 10.1016/j.ejca.2016.12.037. Epub 2017 Feb 17.
5
Modelling a population with Barrett's oesophagus from oesophageal adenocarcinoma incidence data.根据食管腺癌发病率数据对巴雷特食管人群进行建模。
Scand J Gastroenterol. 2007 Mar;42(3):308-17. doi: 10.1080/00365520600884130.
6
[Barrett's oesophagus: endoscopic diagnosis and follow-up].[巴雷特食管:内镜诊断与随访]
Ann Chir. 2006 Jan;131(1):3-6. doi: 10.1016/j.anchir.2005.11.003. Epub 2005 Dec 1.
7
Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.监测 Barrett 食管对肿瘤分期和肿瘤进展患者生存的影响。
Gut. 2016 Apr;65(4):548-54. doi: 10.1136/gutjnl-2014-308802. Epub 2015 Apr 22.
8
The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital.英国一家区综合医院四十年来巴雷特食管监测的演变与结果
Eur J Gastroenterol Hepatol. 2016 Dec;28(12):1365-1373. doi: 10.1097/MEG.0000000000000730.
9
Incidence of adenocarcinoma among patients with Barrett's esophagus.巴雷特食管患者腺癌的发病率。
N Engl J Med. 2011 Oct 13;365(15):1375-83. doi: 10.1056/NEJMoa1103042.
10
Epidemiology and prevention of oesophageal adenocarcinoma.食管腺癌的流行病学和预防。
Scand J Gastroenterol. 2022 Aug;57(8):891-895. doi: 10.1080/00365521.2022.2042594. Epub 2022 Mar 2.

引用本文的文献

1
Global Hypomethylation as Minimal Residual Disease (MRD) Biomarker in Esophageal and Esophagogastric Junction Adenocarcinoma.全基因组低甲基化作为食管及食管胃交界腺癌微小残留病(MRD)生物标志物
Cancers (Basel). 2025 Aug 15;17(16):2668. doi: 10.3390/cancers17162668.
2
Precision Care in Screening, Surveillance, and Overall Management of Barrett's Esophagus.巴雷特食管筛查、监测及整体管理中的精准医疗
J Pers Med. 2025 Jul 22;15(8):327. doi: 10.3390/jpm15080327.
3
Chemoprevention of Barrett's Esophagus: a Systematic Review and Comprehensive Assessment of Bias.
巴雷特食管的化学预防:系统评价与偏倚综合评估
Dis Esophagus. 2025 Jul 3;38(4). doi: 10.1093/dote/doaf062.
4
The comparative study of Stretta radiofrequency and anti-reflux mucosectomy in the management of intractable gastroesophageal reflux disease: a single-center retrospective study from Korea.Stretta射频与抗反流黏膜切除术治疗难治性胃食管反流病的比较研究:一项来自韩国的单中心回顾性研究
Clin Endosc. 2025 May;58(3):409-417. doi: 10.5946/ce.2024.163. Epub 2025 May 7.
5
Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells.食管腺癌从前体病变干细胞的演变
Gastroenterology. 2025 Aug;169(2):277-293.e4. doi: 10.1053/j.gastro.2025.02.032. Epub 2025 Mar 14.
6
Surveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease-Specific Mortality.在一个专家中心对巴雷特食管患者进行监测与较低的疾病特异性死亡率相关。
United European Gastroenterol J. 2025 Mar;13(2):220-228. doi: 10.1002/ueg2.12759. Epub 2025 Feb 13.
7
Community assembly modeling of microbial evolution within Barrett's esophagus and esophageal adenocarcinoma.巴雷特食管和食管腺癌中微生物进化的群落组装建模
bioRxiv. 2025 Jan 16:2025.01.14.633020. doi: 10.1101/2025.01.14.633020.
8
Identification of as a Potential Biomarker for Progression from Barrett's Esophagus to Esophageal Adenocarcinoma: A Comprehensive Bioinformatic Analysis.鉴定[具体内容]作为从巴雷特食管进展为食管腺癌的潜在生物标志物:一项全面的生物信息学分析。 (注:原文中“Identification of as a Potential Biomarker...”这里“Identification of”后面缺少具体所鉴定的内容)
Diagnostics (Basel). 2024 Dec 19;14(24):2863. doi: 10.3390/diagnostics14242863.
9
Liquid biopsy to identify Barrett's oesophagus, dysplasia and oesophageal adenocarcinoma: the multicentre study.液体活检用于识别巴雷特食管、发育异常和食管腺癌:多中心研究
Gut. 2025 Jan 17;74(2):169-181. doi: 10.1136/gutjnl-2024-333364.
10
Nomogram for predicting reflux esophagitis with routine metabolic parameters: a retrospective study.利用常规代谢参数预测反流性食管炎的列线图:一项回顾性研究
Arch Med Sci. 2024 Apr 30;20(4):1089-1100. doi: 10.5114/aoms/175536. eCollection 2024.